97 related articles for article (PubMed ID: 12934314)
21. Lipid lowering therapy in women at risk of coronary disease.
Davis SR; Newman A
Clin Endocrinol (Oxf); 1999 Mar; 50(3):405-6. PubMed ID: 10435069
[No Abstract] [Full Text] [Related]
22. Drospirenone in HRT?
Drug Ther Bull; 2009 Apr; 47(4):41-4. PubMed ID: 19357298
[TBL] [Abstract][Full Text] [Related]
23. Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women.
Preston RA
Climacteric; 2007 Feb; 10 Suppl 1():32-41. PubMed ID: 17364596
[TBL] [Abstract][Full Text] [Related]
24. Effect of hormone replacement therapy on salivary flow rate, buffer effect and pH on perimenopausal and postmenopausal women.
Laine M; Leimola-Virtanen R
Arch Oral Biol; 1996 Jan; 41(1):91-6. PubMed ID: 8833596
[TBL] [Abstract][Full Text] [Related]
25. Severe pulmonary hypertension in postmenopausal obese women.
Taraseviciute A; Voelkel NF
Eur J Med Res; 2006 May; 11(5):198-202. PubMed ID: 16723293
[TBL] [Abstract][Full Text] [Related]
26. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
Warming L; Ravn P; Christiansen C
Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of the climacteric symptomatology modifications and clinical-instrumental parameters in women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and in surgical menopause treated with estrogen replacement therapy. Part I].
Savoca S; D'Agosta S; Lombardo G
Minerva Ginecol; 2007 Jun; 59(3):205-14. PubMed ID: 17576399
[TBL] [Abstract][Full Text] [Related]
28. Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution.
Genazzani AR; Gambacciani M
Gynecol Endocrinol; 2006 Mar; 22(3):145-50. PubMed ID: 16835076
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.
Karara AH; Hanes V; Alonso A; Ni P; Poola N; Silang R; Blode H; Preston RA
J Clin Pharmacol; 2007 Oct; 47(10):1292-302. PubMed ID: 17906162
[TBL] [Abstract][Full Text] [Related]
30. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
31. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Weber MA; Bakris GL; Dahlöf B; Pitt B; Velazquez E; Gupte J; Lefkowitz M; Hester A; Shi V; Weir M; Kjeldsen S; Massie B; Nesbitt S; Ofili E; Jamerson K
Blood Press; 2007; 16(1):13-9. PubMed ID: 17453747
[TBL] [Abstract][Full Text] [Related]
32. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
33. [Hypotensive effectiveness of therapy combined enalapril and nitrendipine and influence on the quality of life].
Bryl W; Cymerys M; Kujawska-Luczak M; Pupek-Musialik D
Pol Merkur Lekarski; 2005 Mar; 18(105):287-90. PubMed ID: 15997634
[TBL] [Abstract][Full Text] [Related]
34. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
[TBL] [Abstract][Full Text] [Related]
35. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004.
Gu Q; Burt VL; Paulose-Ram R; Dillon CF
Am J Hypertens; 2008 Jul; 21(7):789-98. PubMed ID: 18451806
[TBL] [Abstract][Full Text] [Related]
36. Endometrial response to a cyclic regimen of percutaneous 17beta-estradiol and low-dose vaginal micronized progesterone in women with mild-to-moderate hypertension.
Vilodre LC; Osório Wender MC; Sisson de Castro JA; dos Reis FM; Ruschel S; Magalhães JA; Spritzer PM
Gynecol Endocrinol; 2003 Aug; 17(4):323-8. PubMed ID: 14503977
[TBL] [Abstract][Full Text] [Related]
37. Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 Study.
Kobalava ZD; Kotovskaya YV; Villevalde SV; Moiseev VS;
Curr Med Res Opin; 2009 Sep; 25(9):2229-37. PubMed ID: 19622008
[TBL] [Abstract][Full Text] [Related]
38. Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women.
Sumino H; Ichikawa S; Takahashi T; Sakamoto H; Goto-Onozato K; Koya S; Kanda T; Nara M; Seki K; Murakami M; Kurabayashi M
Maturitas; 2006 Feb; 53(3):306-14. PubMed ID: 16040211
[TBL] [Abstract][Full Text] [Related]
39. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women.
Sumino H; Ichikawa S; Sawada Y; Sakamoto H; Kumakura H; Takayama Y; Sakamaki T; Kurabayashi M
Thromb Res; 2005; 115(5):359-66. PubMed ID: 15733968
[TBL] [Abstract][Full Text] [Related]
40. Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens.
Fernandes EO; Moraes RS; Ferlin EL; Wender MC; Ribeiro JP
Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S172-7. PubMed ID: 15683490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
